vessels but confirmed the presence of distorted and occluded digital arteries. No other inflammatory stigmata were present. She was diagnosed with limited scleroderma, a variant of systemic sclerosis, and the diagnosis of vasculitis was considered.
Medical management of the scleroderma initially included prednisone and methotrexate. Calcium channel and alpha-adrenergic antagonism were attempted to treat her Raynaud's symptoms but without improvement. Sympathectomy and stellate ganglion blockade were performed, with improvement to skin lesions and a reduction in ischemic pain.
Six months prior to the assessment in our institution she developed a distal ulceration of the left second digit. Digital artery Doppler flow signals were absent at the base of the fingers on both hands. Angiography again documented significant vascular compromise, with multiple bilateral digital vessel occlusions. A left cervical sympathetic block produced neither improvement in her symptoms nor any evidence of healing of the ulceration. The pain was progressive and unrelieved by narcotics. In the absence of additional surgical treatment options, amputation was considered.
At the patient's initial visit to the Stanford University Vascular Medicine program, the non-healing digital ulcer on the left second digit was documented ( Figure 1A ). Diffuse skin changes and early ulceration of the right fourth digit were observed ( Figure 1B ). Both distal digits were cyanotic. Topical hyperbaric oxygen therapy was initiated. After one month, the pain was unrelieved and there was progression of the digital lesions. Pus and gangrenous changes were developing on the left second finger, despite antibiotic therapy.
Treprostinil for the treatment of severe digital necrosis in systemic sclerosis

Gregory Engel and Stanley G Rockson
Abstract: We report a case of severe digital ulcerations associated with systemic sclerosis, successfully treated with treprostinil (Remodulin ® ). There was improvement within days of the treatment initiation; complete healing was accomplished after 16 weeks of therapy. Patients with systemic sclerosis and peripheral small vessel disease have limited therapeutic options. Treprostinil is a prostacyclin analogue that can be delivered by subcutaneous infusion and is approved in the USA only for treatment of primary pulmonary hypertension. This report provides an impressive example of an alternative, complementary indication for the use of treprostinil.
Subcutaneous treprostinil (Remodulin ® ) infusion was initiated at a dose of 1.25 ng/kg per min and increased by 1.25 ng/kg per min every seven days. The patient had a dramatic response. One day after the infusion started, she reported resolution of the coloration of the fingers, with return of a normal, pink hue. By day four of treatment, she reported increased warmth in her fingers and noted that some areas of her nail beds were pink for the first time in months. Requirements for analgesia decreased substantially during the first week of therapy. Examination on day 12 disclosed a remarkable improvement. Small areas of dry eschar were present on the left second and right fourth digits, but both were substantially improved (Figure 1 C and D) . The maximal dose of 15 ng/kg per min was achieved during week 12 of treatment; continuous treatment was maintained for 16 weeks, until complete healing of the lesions was achieved. The side effects of treprostinil include pain or bruising at the infusion site, rash, headache, diarrhea, nausea, shortness of breath, fatigue or allergic reactions. Our patient experienced diarrhea which gradually improved with prolonged therapy. In addition to some tenderness at the infusion sites, she developed hyperpigmentation and induration around the abdominal infusion sites but this was not repeated when the infusions were moved to the arms.
Maintenance dosing for one week each month at 15 ng/kg per min was planned but recurrence of a small lesion occurred on the right fourth digit just prior to the first maintenance therapy. Maintenance therapy was increased to an alternate week basis to control the lesions. The infusions continue to be well tolerated after one year of follow-up with a sustained, excellent therapeutic response. 
Discussion
The case under discussion provides evidence of an impressive response of critical digit ischemia to treprostinil therapy, which was undertaken as a last effort to avoid digital amputation. In the USA, the two clinically available prostanoids are epoprostenol (Flolan ® ) and treprostinil (Remodulin). In Europe, the prostacyclin analogue iloprost is also available. Treprostinil has the advantage of not requiring an intravenous infusion and is delivered via a continuous subcutaneous infusion.
Intravenous infusion of prostanoids has been most consistently undertaken in the treatment of primary pulmonary hypertension, where they have been shown to be a life-saving bridge to transplantation. 2 Epoprostenol represents the most potent vasodilator available for this indication; additional pharmacologic benefits include its antiplatelet effects, inhibition of smooth muscle proliferation, and promotion of a remodeling response. 3 Beneficial outcomes have been achieved in pulmonary hypertension arising from a variety of clinical settings, including systemic sclerosis. 4, 5 The first report of a therapeutic response to prostaglandin E 1 (PGE 1 ) in limb ischemia described the responses of five patients with advanced arteriosclerosis obliterans of the lower extremities; improvement was seen in all of the patients. 6 Numerous subsequent studies have been performed. The results of 12 long-term, randomized, open or double-blind trials to compare intra-arterial or intravenous infusions of either PGE 1 , ciprostene, or iloprost with placebo, in patients with advanced chronic limb ischemia, were summarized in 1991. 7 In each of these studies, benefit in at least one end point (relief of rest pain, analgesic consumption or ulcer healing) was demonstrated.
In a meta-analysis of six randomized, controlled trials of iloprost therapy in critical leg ischemia, there was a significant increase in the number of patients alive with both legs at six months' follow-up. 8 Significant benefit, compared to placebo, was also seen in ulcer healing and pain relief. In randomized trials of all other pharmacotherapeutic agents, there has been no demonstrable benefit over placebo therapy.
The largest study of PGE 1 employed a randomized, open-label design for the investigation of a heterogeneous population with critical leg ischemia. 9 Treatment with alprostadil was administered daily for up to 28 days. The combined primary outcome, death and peripheral and cardiocerebrovascular illness was significantly decreased by 13% at discharge but had a non-significant decrease of 8% after six months. Most of the observed benefit was from recovery from critical limb ischemia.
Studies of a specific role in digital ischemia are smaller but also demonstrate benefit. Iloprost has shown a trend toward improvement in digital blood flow 10 and lessens the number and severity of attacks of Raynaud's phenomenon in systemic sclerosis. 11, 12 Patients with digital ulcerations have had symptomatic improvements and ulcer healing with iloprost. 13, 14 Intravenous iloprost was shown to prevent imminent gangrene and led to complete healing of ischemic digital ulcers in several patients. 15 For the most part, these studies have evaluated short-term responses to intravenous iloprost, but other studies have also found long-term benefit. In 30 patients, long-term treatment over a median of three years, with maintenance infusions every three weeks, was effective for ischemic ulcers and Raynaud's phenomenon. 16 Prostanoids have a beneficial effect on both the macro-and microcirculation. Prostanoids benefit vascular disease by inducing vasodilation, increasing intracellular cyclic AMP, and by preventing smooth muscle cell proliferation. The microcirculatory disturbances of systemic sclerosis appear to reflect a fibrotic process initiated by infiltrating perivascular mononuclear cells. 17 There is associated platelet aggregation, leukocyte activation and endothelial dysfunction. Iloprost has been shown to reduce the activation of endothelial cells and of the coagulation cascade, which may help to explain the improvement in microvascular functional capacity and the potential for long-term clinical benefit. 18 Iloprost blocks production of connective tissue growth factor normally induced by TGF-␤ and involved in the skin fibrosis seen in scleroderma. 19 
Limitations
Although the patient had a dramatic improvement in the digital lesions, which appears to be directly related to the treprostinil treatment, we do not have objective evidence of increased blood flow in the digits that correlates with wound healing. This patient also had a form of limited scleroderma and patients with other subtypes of systemic sclerosis may respond differently to treatment. Most importantly, this is a single case report. Larger patient groups and studies and eventually randomized trials will be needed to definitely establish the role of treprostinil in the treatment of digital necrosis in systemic sclerosis. Additionally, other treatment options must be considered. Bosentan, an orally administered endothelin-receptor antagonist, has shown some potential to treat digital ulcers in scleroderma in preliminary studies 20 and is currently being evaluated in a randomized, multicenter clinical trial.
Conclusion
Treprostinil has the potential to provide all of the mechanistic benefits of iloprost. With its availability Treprostinil for digital necrosis 31 in a form that permits patient-managed, subcutaneous delivery, this drug represents an excellent therapeutic alternative in the approach to these difficult patients. The case under discussion illustrates the potential for prompt and effective initial control of digital ischemia, as well as the promise of strategies to provide long-term maintenance relief from recurrent disease stigmata.
